DE60217322T2
(en)
|
2001-04-27 |
2007-10-04 |
Zenyaku Kogyo K.K. |
Heterocyclic compound and antitumor agent containing it as an active ingredient
|
JP4493503B2
(en)
*
|
2002-10-25 |
2010-06-30 |
全薬工業株式会社 |
Heterocyclic compounds and antitumor agents containing the same as active ingredients
|
DK1741714T3
(en)
*
|
2004-03-31 |
2013-04-15 |
Zenyaku Kogyo Kk |
Heterocyclic compound and anti-malignant turmeric agent containing this as active ingredient
|
CA2599879C
(en)
*
|
2005-03-11 |
2013-07-02 |
Zenyaku Kogyo Kabushikikaisha |
Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
|
RU2386630C2
(en)
|
2005-07-01 |
2010-04-20 |
Айрм Ллк |
Compounds and compositions as protein tyrosine kinase inhibitors
|
DE602006017574D1
(en)
*
|
2005-07-26 |
2010-11-25 |
Vertex Pharma |
USE AS PROTEIN KINASE INHIBITORS BENZIMIDAZOLE
|
US20070244110A1
(en)
*
|
2006-04-14 |
2007-10-18 |
Zenyaku Kogyo Kabushiki Kaisha |
Treatment of prostate cancer, melanoma or hepatic cancer
|
WO2008032036A1
(en)
*
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032072A1
(en)
*
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
US20090270390A1
(en)
*
|
2006-09-14 |
2009-10-29 |
Astrazeneca |
Pyrimidine derivatives
|
JP2010503648A
(en)
*
|
2006-09-14 |
2010-02-04 |
アストラゼネカ アクチボラグ |
2-Benzimidazolyl-6-morpholino-4- (azetidine, pyrrolidine, piperidine, or azepine) pyrimidine derivatives as PI3K and MTOR inhibitors for the treatment of proliferative diseases
|
WO2008032077A1
(en)
*
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
WO2008032027A1
(en)
*
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
WO2008032091A1
(en)
*
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
PT2409975E
(en)
|
2007-11-22 |
2015-07-27 |
Zenyaku Kogyo Kk |
Solid dispersions comprising an amorphous body composed of a heterocyclic anti-tumor compound
|
JP2011515462A
(en)
*
|
2008-03-27 |
2011-05-19 |
アウククランド ウニセルビセス リミテッド |
Substituted pyrimidines and triazines and their use in cancer therapy
|
WO2009143317A1
(en)
|
2008-05-23 |
2009-11-26 |
Wyeth |
Triazine compounds as p13 kinase and mtor inhibitors
|
US10022381B2
(en)
|
2008-05-23 |
2018-07-17 |
Pfizer Inc. |
Triazine compounds as PI3 kinase and mTOR inhibitors
|
TWI378933B
(en)
|
2008-10-14 |
2012-12-11 |
Daiichi Sankyo Co Ltd |
Morpholinopurine derivatives
|
GB2465405A
(en)
*
|
2008-11-10 |
2010-05-19 |
Univ Basel |
Triazine, pyrimidine and pyridine analogues and their use in therapy
|
HUP0800768A2
(en)
|
2008-12-18 |
2012-08-28 |
Bioblocks Magyarorszag Gyogyszerkemiai Es Fejlesztoe Kft |
1,3-heterocycles condensed with monoterpene skeleton, their use and pharmaceutical compositions comprising such compounds
|
KR20110120286A
(en)
|
2009-02-12 |
2011-11-03 |
아스텔라스세이야쿠 가부시키가이샤 |
Hetero ring derivative
|
CA2756067A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
EP2451802A1
(en)
|
2009-07-07 |
2012-05-16 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
GB201004200D0
(en)
|
2010-03-15 |
2010-04-28 |
Univ Basel |
Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
|
GB201007227D0
(en)
|
2010-04-30 |
2010-06-16 |
Univ Basel |
Piperazinotriazines
|
JP5765342B2
(en)
*
|
2010-08-10 |
2015-08-19 |
アステラス製薬株式会社 |
Heterocyclic compounds
|
WO2012044641A1
(en)
*
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
WO2012135160A1
(en)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
|
WO2013047411A1
(en)
*
|
2011-09-29 |
2013-04-04 |
富士フイルム株式会社 |
Novel triazine derivative and ultraviolet absorbent
|
EP2790705B1
(en)
|
2011-12-15 |
2017-12-06 |
Novartis AG |
Use of inhibitors of the activity or function of pi3k
|
WO2014055647A1
(en)
*
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
CN106661039B
(en)
|
2014-02-28 |
2019-09-13 |
林伯士拉克许米公司 |
2 (TYK2) inhibitor of tyrosine protein matter kinases and its purposes
|
CN106715456B
(en)
|
2014-08-12 |
2023-08-29 |
莫纳什大学 |
Prodrugs of directed lymphatics
|
MA40933A
(en)
*
|
2014-11-11 |
2017-09-19 |
Piqur Therapeutics Ag |
DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES
|
TWI788655B
(en)
|
2015-02-27 |
2023-01-01 |
美商林伯士拉克許米公司 |
Tyk2 inhibitors and uses thereof
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
JP6802263B2
(en)
|
2015-09-02 |
2020-12-16 |
ニンバス ラクシュミ, インコーポレイテッド |
TYK2 inhibitor and its use
|
CN114031658A
(en)
|
2015-09-08 |
2022-02-11 |
莫纳什大学 |
Lymphatic prodrugs
|
WO2017044720A1
(en)
|
2015-09-11 |
2017-03-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
CN105175410B
(en)
*
|
2015-10-14 |
2018-01-05 |
湖南华腾制药有限公司 |
Compound in triazine class and preparation method thereof and antitumor application thereof
|
JP6800968B2
(en)
|
2015-10-23 |
2020-12-16 |
ナビター ファーマシューティカルズ, インコーポレイテッド |
Sestrin-GATOR2 interaction modulator and its use
|
WO2017106352A1
(en)
|
2015-12-14 |
2017-06-22 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of mthfd2 and uses thereof
|
EP3389652B1
(en)
|
2015-12-14 |
2022-09-28 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
PL3426244T3
(en)
|
2016-03-09 |
2023-09-25 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
WO2017156165A1
(en)
|
2016-03-09 |
2017-09-14 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
CN109153722A
(en)
|
2016-04-08 |
2019-01-04 |
X4 制药有限公司 |
Method for treating cancer
|
CN109641838A
(en)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
CXCR4 inhibitor and application thereof
|
CN109640988A
(en)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
CXCR4 inhibitor and application thereof
|
CN116554168A
(en)
|
2016-06-21 |
2023-08-08 |
X4 制药有限公司 |
CXCR4 inhibitors and uses thereof
|
TW201825465A
(en)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
Phosphatidylinositol 3-kinase inhibitors
|
TW201813963A
(en)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
Phosphatidylinositol 3-kinase inhibitors
|
TW201815787A
(en)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
Phosphatidylinositol 3-kinase inhibitors
|
EP3848370A3
(en)
|
2016-10-14 |
2021-09-15 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
CN110300590A
(en)
|
2016-10-21 |
2019-10-01 |
林伯士拉克许米公司 |
TYK2 inhibitor and application thereof
|
WO2018089499A1
(en)
|
2016-11-08 |
2018-05-17 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
WO2018115203A1
(en)
|
2016-12-23 |
2018-06-28 |
Bicyclerd Limited |
Peptide derivatives having novel linkage structures
|
US10624968B2
(en)
|
2017-01-06 |
2020-04-21 |
Bicyclerd Limited |
Compounds for treating cancer
|
WO2018131659A1
(en)
*
|
2017-01-11 |
2018-07-19 |
国立研究開発法人国立がん研究センター |
Immunotherapeutic agent
|
TW202321243A
(en)
|
2017-03-08 |
2023-06-01 |
美商林伯士拉克許米公司 |
Methods for production of tyk2 inhibitors
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
US11339144B2
(en)
|
2017-04-10 |
2022-05-24 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl Rheb inhibitors and uses thereof
|
JP7179015B2
(en)
|
2017-04-26 |
2022-11-28 |
ナビター ファーマシューティカルズ, インコーポレイテッド |
Modulators for the Sestrin-GATOR2 reciprocal locus and uses thereof
|
WO2018197893A1
(en)
|
2017-04-27 |
2018-11-01 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
MX2019013862A
(en)
|
2017-05-23 |
2020-01-20 |
Mei Pharma Inc |
Combination therapy.
|
CN111032678A
(en)
|
2017-06-26 |
2020-04-17 |
拜西克尔德有限公司 |
Bicyclic peptide ligands with detectable moieties and uses thereof
|
JP7216705B2
(en)
|
2017-07-28 |
2023-02-02 |
ニンバス ラクシュミ, インコーポレイテッド |
TYK2 inhibitors and methods of use thereof
|
US20200291096A1
(en)
|
2017-08-14 |
2020-09-17 |
Bicyclerd Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
US20200283482A1
(en)
|
2017-08-14 |
2020-09-10 |
Bicyclerd Limited |
Bicyclic peptide ligand prr-a conjugates and uses thereof
|
CA3072476A1
(en)
|
2017-08-14 |
2019-02-21 |
Mei Pharma, Inc. |
Combination therapy
|
CA3077739A1
(en)
|
2017-08-29 |
2019-03-07 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
EP3684366A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
AU2018338314A1
(en)
|
2017-09-22 |
2020-04-09 |
Kymera Therapeutics, Inc |
Protein degraders and uses thereof
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
US10874743B2
(en)
|
2017-12-26 |
2020-12-29 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
KR20200116481A
(en)
|
2018-01-29 |
2020-10-12 |
메르크 파텐트 게엠베하 |
GCN2 inhibitors and uses thereof
|
SG11202006832YA
(en)
|
2018-01-29 |
2020-08-28 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
CN117304157A
(en)
|
2018-02-27 |
2023-12-29 |
阿塔克斯生物制药有限公司 |
Chromene derivatives as inhibitors of TCR-NCK interactions
|
RS63281B1
(en)
|
2018-04-24 |
2022-06-30 |
Merck Patent Gmbh |
Antiproliferation compounds and uses thereof
|
JP7479293B2
(en)
|
2018-04-24 |
2024-05-08 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Pteridinone compounds and uses thereof
|
WO2019241789A1
(en)
|
2018-06-15 |
2019-12-19 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
JP2022500499A
(en)
|
2018-09-07 |
2022-01-04 |
ピク セラピューティクス, インコーポレイテッド |
EIF4E Inhibitors and Their Use
|
AU2019360941A1
(en)
|
2018-10-15 |
2021-04-29 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
US10919937B2
(en)
|
2018-10-23 |
2021-02-16 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
EP3870158A4
(en)
|
2018-10-24 |
2022-08-10 |
Navitor Pharmaceuticals, Inc. |
Polymorphic compounds and uses thereof
|
US11053241B2
(en)
|
2018-11-30 |
2021-07-06 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
BR112021010484A2
(en)
|
2018-11-30 |
2021-08-24 |
Kymera Therapeutics, Inc. |
Irak degraders and their uses
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
EP3914357A4
(en)
|
2019-01-23 |
2022-10-12 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
CA3135569A1
(en)
|
2019-04-02 |
2020-10-08 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
US11485750B1
(en)
|
2019-04-05 |
2022-11-01 |
Kymera Therapeutics, Inc. |
STAT degraders and uses thereof
|
KR20220034739A
(en)
|
2019-05-31 |
2022-03-18 |
이케나 온콜로지, 인코포레이티드 |
TEAD inhibitors and uses thereof
|
TW202110485A
(en)
|
2019-07-30 |
2021-03-16 |
英商拜西可泰克斯有限公司 |
Heterotandem bicyclic peptide complex
|
CN115038688A
(en)
|
2019-09-11 |
2022-09-09 |
文森雷生物科学股份有限公司 |
USP30 inhibitors and uses thereof
|
KR20220105631A
(en)
|
2019-09-13 |
2022-07-27 |
님버스 새턴 인코포레이티드 |
HPK1 antagonists and uses thereof
|
AU2020376950A1
(en)
|
2019-11-01 |
2022-06-09 |
Navitor Pharmaceuticals, Inc. |
Methods of treatment using an mTORC1 modulator
|
AU2020397938A1
(en)
|
2019-12-05 |
2022-06-23 |
Janssen Pharmaceutica Nv |
Rapamycin analogs and uses thereof
|
BR112022011651A2
(en)
|
2019-12-17 |
2022-08-23 |
Kymera Therapeutics Inc |
IRAK DEGRADATORS AND USES THEREOF
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
IL294150A
(en)
|
2019-12-23 |
2022-08-01 |
Kymera Therapeutics Inc |
Smarca degraders and uses thereof
|
CN115348864A
(en)
|
2020-02-05 |
2022-11-15 |
纯技术Lyt股份有限公司 |
Lipid prodrugs of neurosteroids
|
KR20220164706A
(en)
|
2020-03-03 |
2022-12-13 |
피아이씨 테라퓨틱스 인코포레이티드 |
EIF4E Inhibitors and Uses Thereof
|
EP4121043A1
(en)
|
2020-03-19 |
2023-01-25 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
TW202210483A
(en)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Crystalline forms of irak degraders
|
CA3186504A1
(en)
|
2020-08-17 |
2022-02-24 |
Stephen J. Blakemore |
Bicycle conjugates specific for nectin-4 and uses thereof
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2022120354A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
AU2022216810A1
(en)
|
2021-02-02 |
2023-08-24 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
AU2022215844A1
(en)
|
2021-02-02 |
2023-09-14 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
KR20230145446A
(en)
|
2021-02-15 |
2023-10-17 |
카이메라 쎄라퓨틱스 인코포레이티드 |
IRAK4 degrader and its uses
|
JP2024509192A
(en)
|
2021-03-05 |
2024-02-29 |
ニンバス サターン, インコーポレイテッド |
HPK1 antagonists and their uses
|
KR20230172548A
(en)
|
2021-04-16 |
2023-12-22 |
이케나 온콜로지, 인코포레이티드 |
MEK inhibitors and uses thereof
|
WO2023028238A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
IL310924A
(en)
|
2021-08-25 |
2024-04-01 |
Pic Therapeutics Inc |
Eif4e inhibitors and uses thereof
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023230205A1
(en)
|
2022-05-25 |
2023-11-30 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|